What's Happening?
A significant number of U.S. employers are re-evaluating their coverage for GLP-1 weight-loss drugs due to escalating costs. According to WTW's 2026 Best Practices in Healthcare Survey, 16% of employers covering these drugs are considering dropping the benefit,
an increase from 9% in the previous year. This survey focused on employers with over 100 employees, representing approximately 7 million workers. The overall percentage of employers covering GLP-1s for weight loss has also decreased for the first time in three years, falling from 57% in 2025 to 53% in 2026. Employers are facing monthly costs ranging from mid-$500s to mid-$600s per user for these medications. Bank of America CEO Brian Moynihan noted in August 2026 that the company's spending on GLP-1s has risen to $250 million or more from zero. A separate survey by the Business Group on Health (BGH) indicates that 14% of employers have already dropped or plan to drop this coverage by 2027.
Why It's Important?
This trend of employers reducing or eliminating coverage for GLP-1 weight-loss drugs has substantial implications for the pharmaceutical industry, employer-sponsored health plans, and individual patients. For pharmaceutical companies like Eli Lilly and Novo Nordisk, a shift away from employer coverage could impact their revenue streams, particularly if patients transition to lower-priced cash channels. Eli Lilly, which relies significantly on cash buyers for its Zepbound prescriptions, might be better positioned than Novo Nordisk, which is already cutting cash prices to maintain market share. For employers, the decision to cut coverage is driven by the desire to mitigate rising healthcare costs, with WTW projecting an 11.1% increase in employer health costs in 2027 if no changes are made. This could lead to a reduction in benefits for employees, potentially shifting the financial burden of these medications directly onto individuals. The move also highlights a broader challenge in managing the costs of new, effective, but expensive pharmaceutical treatments within the U.S. healthcare system.
What's Next?
The coming months will likely see continued scrutiny of employer health benefits and the pricing strategies of pharmaceutical companies. Eli Lilly is scheduled to report its third-quarter results on October 29, followed by Novo Nordisk on November 4. These earnings reports will provide further insight into the financial impact of changing coverage landscapes and the effectiveness of their respective market strategies. If Eli Lilly's 2026 revenue guidance falls below $85.0 billion, it could signal a weakening outlook for the company. Additionally, Novo Nordisk's planned list price cut of approximately 50% on Wegovy, effective January 1, 2027, will be a key factor in how it retains market share. As employers continue to weigh their options, more may transition to direct-to-consumer arrangements, with 28% already planning or considering such a switch. This could lead to a more fragmented market for GLP-1 drugs, with a greater emphasis on individual out-of-pocket payments.
Beyond the Headlines
The evolving landscape of GLP-1 weight-loss drug coverage raises deeper questions about access to innovative medical treatments and the role of employers in healthcare provision. While these drugs offer significant health benefits for many, their high cost presents a dilemma for employers balancing employee well-being with financial sustainability. The potential shift towards patients paying out-of-pocket, even at reduced cash prices, could create a two-tiered system where access is determined by individual financial capacity rather than medical need. This situation could exacerbate health disparities and place a greater burden on individuals already struggling with healthcare expenses. Furthermore, the trend could prompt a broader discussion about pharmaceutical pricing regulations and the need for more sustainable models for covering high-cost medications within the U.S. healthcare system, potentially influencing future policy debates on health insurance and drug affordability.
